Mar 13, 2023 8:00am EDT ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
Mar 07, 2023 8:00am EST ProPhase Labs’ Nebula Genomics Subsidiary Introduces Lowest Ever NGS Pricing of $249 for its Whole Genome Sequencing DNA Test
Mar 01, 2023 8:00am EST ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
Feb 16, 2023 8:00am EST ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
Feb 15, 2023 8:00am EST ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand
Feb 06, 2023 8:00am EST ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
Jan 05, 2023 8:00am EST ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
